Compare Freeport-McMoRan Inc (FCX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Sanofi SA — how do they compare? Freeport-McMoRan Inc trades at $73.37 (market cap $102.16B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Freeport-McMoRan Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Sanofi SA for 94 Days on average.
| FCX | SNY | |
|---|---|---|
Market Cap | $102.16B | $95.18B |
Volume | 9,047,971 | 2,995,646 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $52.34 |
52-Week Low | $38.65 | $39.51 |
Typical Hold Time | 69 Days | 94 Days |
Enterprise Value | $108.44B | $114.48B |
Dividend Yield | 0.84% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freeport-McMoRan (FCX) trades at $71.87, down 0.97% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected shortly. FCX maintains solid profitability with 11.38% net margin and 15.37% ROE, supported by robust operational cash flow of $5.61 billion in 2025. Recent news highlights copper's strategic importance for AI infrastructure, positioning FCX to benefit from long-term demand trends.
FCX presents a compelling opportunity with analyst consensus at Buy (61%) and $73.27 price target, offering 2% upside. The company's expansion projects and copper's AI-driven demand create growth potential, though rising production costs and ongoing legal investigation pose risks. Institutional sentiment remains positive given FCX's market leadership and favorable commodity outlook.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
